Daniela Regazzo, Serena Avallone, Cliona P MacSweeney, Eugenia Sergeev, David Howe, Alex Godwood, Kirstie A Bennett, Alastair J H Brown, Matt Barnes, Gianluca Occhi, Mattia Barbot, Diego Faggian, Maria Pia Tropeano, Marco Losa, Giovanni Lasio, Carla Scaroni, Francesca Pecori Giraldi
OBJECTIVE: Somatostatin receptor ligands have come to play a pivotal role in the treatment of both ACTH- and GH-secreting pituitary adenomas. Clinical efficacy averages 30-50%, thus a considerable number of patients with Cushing's disease or acromegaly remain unresponsive to this therapeutic approach. HTL0030310 is a new somatostatin receptor ligand selective for subtype 5 over subtype 2, thus with a different receptor profile compared to clinical somatostatin receptor ligands. DESIGN: Assessment of the effect of HTL0030310 on hormone secretion in human ACTH- and GH-secreting pituitary adenomas in vitro...
January 3, 2024: European Journal of Endocrinology